AXIM Biotechnologies, Inc. (AXIM)
USD 0.01
(21.43%)
USD 0.01
(21.43%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 5.65 Million USD | -0.11% |
| 2022 | 5.66 Million USD | -15.69% |
| 2021 | 6.71 Million USD | 6.49% |
| 2020 | 6.3 Million USD | 3.38% |
| 2019 | 6.1 Million USD | 4.02% |
| 2018 | 5.86 Million USD | -8.34% |
| 2017 | 6.4 Million USD | 261.16% |
| 2016 | 1.77 Million USD | 22.24% |
| 2015 | 1.45 Million USD | 38.1% |
| 2014 | 1.05 Million USD | 2000.0% |
| 2013 | 50 Thousand USD | 0.0% |
| 2012 | 50 Thousand USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 6.4 Million USD | 0.59% |
| 2024 Q1 | 6.37 Million USD | 12.59% |
| 2023 FY | 5.65 Million USD | -0.11% |
| 2023 Q2 | 5.71 Million USD | 7.0% |
| 2023 Q4 | 5.65 Million USD | -2.65% |
| 2023 Q3 | 5.81 Million USD | 1.62% |
| 2023 Q1 | 5.34 Million USD | -5.63% |
| 2022 Q3 | 5.61 Million USD | 0.36% |
| 2022 FY | 5.66 Million USD | -15.69% |
| 2022 Q4 | 5.66 Million USD | 0.95% |
| 2022 Q1 | 5.55 Million USD | -17.36% |
| 2022 Q2 | 5.59 Million USD | 0.69% |
| 2021 Q3 | 6.26 Million USD | 3.98% |
| 2021 Q4 | 6.71 Million USD | 7.29% |
| 2021 Q1 | 6.37 Million USD | 1.09% |
| 2021 Q2 | 6.02 Million USD | -5.57% |
| 2021 FY | 6.71 Million USD | 6.49% |
| 2020 FY | 6.3 Million USD | 3.38% |
| 2020 Q1 | 6.43 Million USD | 5.4% |
| 2020 Q2 | 5.61 Million USD | -12.74% |
| 2020 Q3 | 6.24 Million USD | 11.16% |
| 2020 Q4 | 6.3 Million USD | 1.11% |
| 2019 Q4 | 6.1 Million USD | 1.23% |
| 2019 FY | 6.1 Million USD | 4.02% |
| 2019 Q2 | 5.95 Million USD | 0.23% |
| 2019 Q1 | 5.94 Million USD | 1.25% |
| 2019 Q3 | 6.02 Million USD | 1.25% |
| 2018 Q3 | 4.63 Million USD | -17.17% |
| 2018 FY | 5.86 Million USD | -8.34% |
| 2018 Q4 | 5.86 Million USD | 26.65% |
| 2018 Q2 | 5.59 Million USD | -11.92% |
| 2018 Q1 | 6.35 Million USD | -0.8% |
| 2017 FY | 6.4 Million USD | 261.16% |
| 2017 Q2 | 5.88 Million USD | 223.25% |
| 2017 Q3 | 6.14 Million USD | 4.27% |
| 2017 Q4 | 6.4 Million USD | 4.24% |
| 2017 Q1 | 1.82 Million USD | 2.79% |
| 2016 Q4 | 1.77 Million USD | 26.78% |
| 2016 Q2 | 1.38 Million USD | -4.58% |
| 2016 Q1 | 1.45 Million USD | 0.0% |
| 2016 FY | 1.77 Million USD | 22.24% |
| 2016 Q3 | 1.39 Million USD | 1.05% |
| 2015 Q3 | 1.45 Million USD | 0.0% |
| 2015 Q4 | 1.45 Million USD | 0.0% |
| 2015 Q2 | 1.45 Million USD | 38.1% |
| 2015 Q1 | 1.05 Million USD | 0.0% |
| 2015 FY | 1.45 Million USD | 38.1% |
| 2014 Q1 | 50 Thousand USD | 0.0% |
| 2014 Q4 | 1.05 Million USD | 0.0% |
| 2014 Q3 | 1.05 Million USD | 2000.0% |
| 2014 Q2 | 50 Thousand USD | 0.0% |
| 2014 FY | 1.05 Million USD | 2000.0% |
| 2013 FY | 50 Thousand USD | 0.0% |
| 2013 Q4 | 50 Thousand USD | 0.0% |
| 2013 Q3 | 50 Thousand USD | 0.0% |
| 2013 Q1 | 50 Thousand USD | 0.0% |
| 2013 Q2 | 50 Thousand USD | 0.0% |
| 2012 Q4 | 50 Thousand USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 FY | 50 Thousand USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -2113.822% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -321.139% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -360.643% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 86.954% |
| GB Sciences, Inc. | 1.75 Million USD | -221.624% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Skye Bioscience, Inc. | 4.61 Million USD | -22.601% |
| Zenith Capital Corp. | 10.22 Thousand USD | -55238.416% |
| Agentix Corp. | 50 Thousand USD | -11216.706% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 3.623% |
| Biomind Labs Inc. | 735.54 Thousand USD | -669.277% |
| ContraFect Corporation | 2.88 Million USD | -96.402% |
| CSL Limited | 12.18 Billion USD | 99.954% |
| CytoDyn Inc. | 30.07 Million USD | 81.186% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -1473.032% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -798.042% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 87.58% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -496.702% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -648.257% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 80.991% |
| SQZ Biotechnologies Company | 27.47 Million USD | 79.402% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -537.156% |
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 86.267% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -143.27% |
| Mesoblast Limited | 118.7 Million USD | 95.233% |
| Marizyme, Inc. | 18.71 Million USD | 69.77% |
| Genus plc | 233.1 Million USD | 97.573% |
| Pharming Group N.V. | 171.54 Million USD | 96.702% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -654.447% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -291.224% |
| IMV Inc. | 28.88 Million USD | 80.41% |
| MultiCell Technologies, Inc. | 202.58 USD | -2793044.93% |
| ONE Bio Corp. | 19.71 Million USD | 71.299% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 90.158% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 82.906% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -86.979% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 56.464% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -3898.327% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -21900.673% |
| Alpha Cognition Inc. | 1.22 Million USD | -363.658% |
| Enzolytics Inc. | 996.33 Thousand USD | -467.915% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 20 Million USD | 71.708% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 19.999% |
| Genscript Biotech Corporation | 417.73 Million USD | 98.645% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -37.273% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -1308.079% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -135.989% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -2367.761% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -3706.391% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -93.092% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -4076.307% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.49 Million USD | -278.548% |
| Q BioMed Inc. | 4.1 Million USD | -37.673% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 72.165% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 91.635% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 4.71 Million USD | -20.099% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -150.549% |
| HST Global, Inc. | 98.31 Thousand USD | -5655.096% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -2174.989% |
| Halberd Corporation | 150 Thousand USD | -3672.235% |
| Resverlogix Corp. | 6.49 Million USD | 12.828% |
| Cell Source, Inc. | 9.25 Million USD | 38.856% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -108.895% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -2720.489% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.19 Million USD | -157.212% |
| Kadimastem Ltd | 891.22 Thousand USD | -534.895% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -2582.002% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -2161.695% |
| LadRx Corporation | 33.6 Thousand USD | -16737.33% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -648.257% |
| Affymax, Inc. | - USD | -Infinity% |
| Itoco Inc. | 228.37 Thousand USD | -2377.637% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -13.553% |
| Mobile Lads Corp. | 484.28 Thousand USD | -1068.396% |
| International Stem Cell Corporation | 4.17 Million USD | -35.432% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | 1.92 Million USD | -193.94% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -1508.186% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 27.642% |
| SYBLEU INC | 477.5 Thousand USD | -1084.995% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -4519.064% |
| Rebus Holdings, Inc. | 310 Thousand USD | -1725.275% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -19.493% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -8965.985% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -159.45% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 31.958% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 34.09% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -263.769% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -2011.326% |
| Neutra Corp. | 54.15 Thousand USD | -10348.248% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -209.2% |
| PureTech Health plc | 25.51 Million USD | 77.821% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -362.198% |
| IXICO plc | 472.02 Thousand USD | -1098.745% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 63.497% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 90.912% |
| CSL Limited | 12.18 Billion USD | 99.954% |
| Cellectis S.A. | 92.77 Million USD | 93.901% |